NCT00468182View on ClinicalTrials.gov

Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis

CompletedOBSERVATIONAL

Enrollment

24

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

Multiple Sclerosis

Interventions

DRUG

Interferon-beta 1b (Betaseron)

Treatment of patients with FDA-approved Rx

Trial Locations (1)

08901

Rutgers-RWJMS, New Brunswick

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

Rutgers, The State University of New Jersey

OTHER